دورية أكاديمية
Are patients in haemodialysis good candidates for immunotherapy treatment?
| العنوان: | Are patients in haemodialysis good candidates for immunotherapy treatment? |
|---|---|
| المؤلفون: | Fernandez-Diaz AB; Medical Onoclogy Service., Cunquero-Tomas AJ; Medical Onoclogy Service., Garcia-Medina A; Department of Medical Oncology, National Medical Center 'November 20' of the Institute of Security and Social Services of State Workers, National Autonomoues University of Mexico (UNAM), Mexico City, Mexico., Ferrer-Guillen B; Dermatology Service, Consorcio Hospital General Universitario de Valencia, Spain., Berrocal A; Medical Onoclogy Service. |
| المصدر: | Melanoma research [Melanoma Res] 2019 Oct; Vol. 29 (5), pp. 553-555. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9109623 Publication Model: Print Cited Medium: Internet ISSN: 1473-5636 (Electronic) Linking ISSN: 09608931 NLM ISO Abbreviation: Melanoma Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Lippincott Williams & Wilkins Original Publication: Oxford, UK : Rapid Communications of Oxford, 1991- |
| مواضيع طبية MeSH: | Renal Dialysis*, Antibodies, Monoclonal/*therapeutic use , Immunotherapy/*methods , Melanoma/*drug therapy , Nivolumab/*therapeutic use , Skin Neoplasms/*drug therapy, Aged, 80 and over ; Diabetic Nephropathies/complications ; Female ; Humans ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Treatment Outcome ; Melanoma, Cutaneous Malignant |
| مستخلص: | The effectiveness and safety of nivolumab, an anti-programmed cell death protein 1 mAbmonoclonal antibody, in patients with renal replacement therapy is unclear, with limited evidence supporting its usefulness in this context. Therefore, we report a case of recurrent metastatic melanoma in a patient on haemodialysis successfully treated with nivolumab. As seen in patients without renal impairment, significant regression of the lesions was observed after 8 weeks of treatment, reaching complete clinical response after 4 months. During follow-up, no dose adjustment, delay, or treatment suspension due to toxicity were required. |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 31YO63LBSN (Nivolumab) |
| تواريخ الأحداث: | Date Created: 20190830 Date Completed: 20200708 Latest Revision: 20240229 |
| رمز التحديث: | 20240229 |
| DOI: | 10.1097/CMR.0000000000000616 |
| PMID: | 31464825 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1473-5636 |
|---|---|
| DOI: | 10.1097/CMR.0000000000000616 |